Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 38
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Rev. Soc. Cardiol. Estado de Säo Paulo ; 29(2 (Supl)): 201-201, abr.-jun. 2019. ilus
Artigo em Português | LILACS | ID: biblio-1009930

RESUMO

A prótese de Star-Edwards foi a primeira válvula mecânica a ser implantada no mundo, no ano de 1960. Cerca de 200.000 pacientes foram beneficiados com esse modelo, porém, caiu em desuso por suas frequentes complicações como hemólise, anemia e tromboembolismos, apesar de sua notável durabilidade. Neste artigo apresentamos um caso de paciente com a maior durabilidade com manutenção da funcionalidade da prótese S-E, já relatado na literatura. O paciente fez o seguimento cardiológico corretamente, bem como usou a anticoagulação adequada. Apresentou disfunção de outras valvas, porém a prótese S-E manteve-se estável e funcional. Inclusive, necessitou de cirurgia para troca valvar mitral, mas não da prótese de S-E em posição aórtica. Este relato foi realizado através da história clínica do paciente e do levantamento de dados da literatura sobre próteses valvares e sua durabilidade. Existem relatos de durabilidade de próteses valvares com aproximadamente 30 a 40 anos, mas nenhum relato próximo ou igual a este com 49 anos de durabilidade. A importância dos cuidados pós-operatórios, uso correto dos anticoagulantes e o seguimento clínico para controle das possíveis complicações da prótese, foi mostrada neste artigo através do relato desse caso


In 1960, the Starr-Edwards prosthesis became the first mechanical valve to be implanted, worldwide. Roughly 200,000 patients benefited from this model. However, it has now fallen out of use due to its frequent complications, such as hemolysis, anemia and thromboembolisms, despite its noteworthy durability. In this article, we present a case of a patient with the longest durability with maintenance of functionality of the S-E prosthesis reported in the literature. The patient had correctly followed the cardiological follow-up, including adequate use of anti-coagulant medications. The patient presented dysfunction in other valves, but the S-E prosthesis remained stable and functional. The patient even required mitral valve replacement surgery, but not for the S-E prosthesis in the aortic position. This report was based on patient's clinical history and a survey of the literature data on valve prostheses and their durability. There are reports of prostheses remaining stable for approximately 30 to 40 years, but none that came close to this one, which had lasted for 49 years The importance of postoperative care, the correct use of anti-coagulant medicines, and clinical follow-up to minimize the possible complications of the prosthesis, were shown in this article through this case report


Assuntos
Humanos , Masculino , Idoso , Próteses Valvulares Cardíacas , Valvas Cardíacas , Valva Aórtica , Estenose da Valva Aórtica/cirurgia , Ecocardiografia/métodos , Doenças das Valvas Cardíacas , Anticoagulantes/uso terapêutico
2.
In. Consolim-Colombo, Fernanda M; Saraiva, José Francisco Kerr; Izar, Maria Cristina de Oliveira. Tratado de Cardiologia: SOCESP / Cardiology Treaty: SOCESP. São Paulo, Manole, 4ª; 2019. p.692-697.
Monografia em Português | LILACS, Sec. Est. Saúde SP, SESSP-IDPCPROD, Sec. Est. Saúde SP | ID: biblio-1009475
3.
Adv Simul (Lond) ; 3: 23, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-30505467

RESUMO

Background: During in situ simulation, interprofessional care teams practice in an area where clinical care occurs. This study aimed to detect latent safety threats (LST) in a training program, which combined in situ simulation scenarios with just-in-time and just-in-place self-directed task training in an emergency department. We hypothesized this simulation-based training in actual care areas allows the detection of at least one LST per simulation scenario. Methods: This prospective observational study (April 2015-March 2016) involved 135 physicians, nurses, and nurse technicians. Training themes selected were arrhythmia, respiratory insufficiency, shock, and cardiopulmonary resuscitation. Simulation weeks occurred every 3 months, with three 10-min scheduled in situ simulation scenarios alternating for each theme daily. The scenarios were followed by co-debriefing by two facilitators (a physician and a nurse). LST were identified by facilitators using a debriefing checklist. Additionally, a room was set up with task-trainers related to each theme. Results: The number participants in scenarios was 114 (84% of the population) and in task-training, 101. The number of scenario cancelations was nine, making the final total number to 49 of 58 proposed. Fifty-six LST were observed, with an average of 1.1 per scenario. LST were divided into four categories: equipment (n = 23, 41.1%), teamwork (n = 12, 21.4%), medication (n = 11, 19.6%), and others (n = 10, 17.9%). There was a higher proportion in equipment-related LST (p < 0.01). Conclusions: The training allowed a high rate of detecting LST regardless of theme. Equipment-related LST were more frequently found.

4.
Arq Bras Cardiol ; 109(3 Supl 1): 1-104, 2017 Jan-Feb.
Artigo em Inglês, Português | MEDLINE | ID: mdl-29044300
5.
Arq. bras. cardiol ; 109(3,supl.1): 1-104, Sept. 2017. tab, graf
Artigo em Inglês | LILACS-Express | ID: biblio-887936
7.
In. Soeiro, Alexandre de Matos; Leal, Tatiana de Carvalho Andreucci Torres; Oliveira Junior, Múcio Tavares de; Kalil Filho, Roberto. Manual da condutas da emergência do InCor: cardiopneumologia / IInCor Emergency Conduct Manual: Cardiopneumology. São Paulo, Manole, 2ª revisada e atualizada; 2017. p.276-283.
Monografia em Português | LILACS | ID: biblio-848468
9.
Rev Assoc Med Bras (1992) ; 62(1): 32-7, 2016 Jan-Feb.
Artigo em Inglês | MEDLINE | ID: mdl-27008490

RESUMO

INTRODUCTION: the EuroSCORE II and STS are the most used scores for surgical risk stratification and indication of transcatheter aortic valve implantation (TAVI). However, its role as a tool for mortality prediction in patients undergoing TAVI is still unclear. OBJECTIVE: to evaluate the performance of the EuroSCORE II and STS as predictors of in-hospital and 30-day mortality in patients undergoing TAVI. METHODS: we included 59 symptomatic patients with severe aortic stenosis that underwent TAVI between 2010 and 2014. The variables were analyzed using Student's t-test and Fisher's exact test and the discriminative power was evaluated using receiver operating characteristic curve (ROC) and area under the curve (AUC) with a 95% confidence interval. RESULTS: mean age was 81±7.3 years, 42.3% men. The mean EuroSCORE II was 7.6±7.3 % and STS was 20.7±10.3%. Transfemoral procedure was performed in 88.13%, transapical in 3.38% and transaortic in 8.47%. In-hospital mortality was 10.1% and 30-day mortality was 13.5%. Patients who died had EuroSCORE II and STS higher than the survivors (33.7±16.7vs. 18.6±7.3% p=0,0001 for STS and 13.9±16.1 vs. 4.8±3.8% p=0.0007 for EuroSCORE II). The STS showed an AUC of 0.81 and the EuroSCORE II of 0.77 and there were no differences in the discrimination ability using ROC curves (p=0.72). CONCLUSION: in this cohort, the STS and EuroSCORE II were predictors of in-hospital and 30-days mortality in patients with severe aortic stenosis undergoing TAVI.


Assuntos
Medição de Risco/métodos , Substituição da Valva Aórtica Transcateter/mortalidade , Idoso , Idoso de 80 Anos ou mais , Estenose da Valva Aórtica/mortalidade , Estenose da Valva Aórtica/cirurgia , Brasil , Feminino , Mortalidade Hospitalar , Humanos , Masculino , Reprodutibilidade dos Testes , Estudos Retrospectivos , Fatores de Risco , Sensibilidade e Especificidade , Substituição da Valva Aórtica Transcateter/efeitos adversos
10.
Rev. Assoc. Med. Bras. (1992) ; 62(1): 32-37, Jan.-Feb. 2016. tab, graf
Artigo em Inglês | LILACS-Express | ID: lil-777440

RESUMO

SUMMARY Introduction: the EuroSCORE II and STS are the most used scores for surgical risk stratification and indication of transcatheter aortic valve implantation (TAVI). However, its role as a tool for mortality prediction in patients undergoing TAVI is still unclear. Objective: to evaluate the performance of the EuroSCORE II and STS as predictors of in-hospital and 30-day mortality in patients undergoing TAVI. Methods: we included 59 symptomatic patients with severe aortic stenosis that underwent TAVI between 2010 and 2014. The variables were analyzed using Student's t-test and Fisher's exact test and the discriminative power was evaluated using receiver operating characteristic curve (ROC) and area under the curve (AUC) with a 95% confidence interval. Results: mean age was 81±7.3 years, 42.3% men. The mean EuroSCORE II was 7.6±7.3 % and STS was 20.7±10.3%. Transfemoral procedure was performed in 88.13%, transapical in 3.38% and transaortic in 8.47%. In-hospital mortality was 10.1% and 30-day mortality was 13.5%. Patients who died had EuroSCORE II and STS higher than the survivors (33.7±16.7vs. 18.6±7.3% p=0,0001 for STS and 13.9±16.1 vs. 4.8±3.8% p=0.0007 for EuroSCORE II). The STS showed an AUC of 0.81 and the EuroSCORE II of 0.77 and there were no differences in the discrimination ability using ROC curves (p=0.72). Conclusion: in this cohort, the STS and EuroSCORE II were predictors of in-hospital and 30-days mortality in patients with severe aortic stenosis undergoing TAVI.


RESUMO Introdução: STS e EuroSCORE II são os escores mais utilizados para a estratificação de risco cirúrgico e indicação do implante de válvula aórtica transcateter (TAVI). Entretanto, seu papel como ferramenta para predição de mortalidade em pacientes submetidos ao TAVI ainda é incerto. Objetivo: avaliar o desempenho do EuroSCORE II e STS como preditores de mortalidade intra-hospitalar em 30 dias em pacientes submetidos ao TAVI. Métodos: 59 pacientes com estenose aórtica importante submetidos ao TAVI entre 2010 e 2014. Variáveis foram analisadas por meio do teste t-Student e teste exato de Fisher, e o poder discriminativo foi avaliado pela curva ROC e área sob a curva, acompanhada de intervalo de confiança de 95%. Resultados: a idade média foi de 81±7,3 anos, 42,3% homens. Média do EuroSCORE II foi de 6,07±7,3%, e do STS, 20,7±10,3%. Procedimento transfemoral foi realizado em 88,13%, transapical, em 3,38% e transaórtico, em 8,47%. A mortalidade intra-hospitalar foi 10,1%, e em 30 dias, 13,5%. Os pacientes que evoluíram para óbito apresentavam STS e EuroSCORE II mais elevados que os sobreviventes (33,7±16,7% vs. 18,6±7,3%; p=0,0001 para STS e 13,9±16,1% vs. 4,8±3,8%; p=0,0007 para EuroSCORE II). O STS apresentou AUC de 0,81, e o EuroSCORE II, 0,77. Não houve diferença na capacidade de discriminação pelas curvas ROC (p=0,72). Conclusão: STS e EuroSCORE II foram preditores de mortalidade intra-hospitalar em 30 dias.

11.
In. Soeiro, Alexandre de Matos; Leal, Tatiana de Carvalho Andreucci; Accorsi, Tarso augusto Duenhas; Gualandro, Danielle Menosi; Oliveira Junior, Múcio Tavares de; Kalil Filho, Roberto. Manual da residência em cardiologia / Manual residence in cardiology. São Paulo, Manole, 2016. p.214-220.
Monografia em Português | LILACS | ID: biblio-971589
13.
Arq Bras Cardiol ; 105(4): 426-9, 2015 Oct.
Artigo em Inglês, Português | MEDLINE | ID: mdl-26559990

RESUMO

Prosthetic thrombosis is a rare complication, but it has high mortality and morbidity. Young women of childbearing age that have prosthetic heart valves are at increased risk of thrombosis during pregnancy due to changes in coagulation factors. Anticoagulation with adequate control and frequent follow-up if pregnancy occurs must be performed in order to prevent complications related to anticoagulant use. Surgery remains the treatment of choice for prosthetic heart valve thrombosis in most clinical conditions. Patients with metallic prosthetic valves have an estimated 5% risk of thrombosis during pregnancy and maternal mortality of 1.5% related to the event. Anticoagulation with vitamin K antagonists during pregnancy is related to varying degrees of complications at each stage of the pregnancy and postpartum periods. Warfarin sodium crosses the placental barrier and when used in the first trimester of pregnancy is a teratogenic agent, causing 1-3% of malformations characterized by fetal warfarin syndrome and also constitutes a major cause of miscarriage in 10-30% of cases. In the third trimester and at delivery, the use of warfarin is associated with maternal and neonatal bleeding in approximately 5 to 15% of cases, respectively. On the other hand, inadequate anticoagulation, including the suspension of the oral anticoagulants aiming at fetal protection, carries a maternal risk of about 25% of metallic prosthesis thrombosis, particularly in the mitral valve. This fact is also due to the state of maternal hypercoagulability with activation of coagulation factors V, VI, VII, IX, X, platelet activity and fibrinogen synthesis, and decrease in protein S levels. The Registry of Pregnancy and Cardiac Disease (ROPAC), assessing 212 pregnant women with metal prosthesis, showed that prosthesis thrombosis occurred in 10 (4.7%) patients and maternal hemorrhage in 23.1%, concluding that only 58% of patients with metallic prosthesis had a complication-free pregnancy.


Assuntos
Anticoagulantes/uso terapêutico , Fatores de Coagulação Sanguínea/efeitos dos fármacos , Próteses Valvulares Cardíacas/efeitos adversos , Período Pós-Parto/efeitos dos fármacos , Complicações Cardiovasculares na Gravidez/prevenção & controle , Trombose/prevenção & controle , Feminino , Idade Gestacional , Heparina/uso terapêutico , Humanos , Metais , Gravidez , Fatores de Risco , Varfarina/uso terapêutico
18.
Int J Infect Dis ; 29: 120-4, 2014 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-25461241

RESUMO

BACKGROUND: Early and accurate risk prediction is an unmet clinical need in patients with infective endocarditis (IE). The aim of this study was to determine the value of B-type natriuretic peptide (BNP) levels obtained on admission for the prediction of in-hospital death in IE patients. METHODS: Between 2009 and 2011, consecutive patients with IE diagnosed using the revised Duke criteria and admitted to the emergency department were evaluated prospectively. BNP levels were measured on admission. Death during hospitalization was the primary endpoint. RESULTS: Among 104 consecutive patients with IE and with available BNP levels, 34 (32.7%) died in hospital. BNP levels were significantly higher in patients who died as compared to survivors (709.0 pg/ml vs. 177.5 pg/ml, p<0.001). The accuracy of BNP to predict death as quantified by the area under the receiver operating characteristics curve was 0.826 (95% confidence interval (CI) 0.747-0.905). The value of BNP was additive to that provided by clinical, microbiological, and echocardiography assessment. On multivariate analysis, new heart failure (hazard ratio (HR) 2.02, 95% CI 1.15-3.57, p=0.015), sepsis (HR 2.10, 95% CI 1.25-3.55, p=0.005), Staphylococcus aureus endocarditis (HR 2.67, 95% CI 1.60-4.45, p<0.001), left ventricular ejection fraction ≤55% (HR 1.63, 95% CI 1.00-2.65, p=0.047), and BNP (HR 1.04, 95% CI 1.02-1.06, p<0.001) were independent predictors of in-hospital mortality. CONCLUSION: Among patients with IE, BNP levels obtained on admission provide incremental value for early and accurate risk prediction.


Assuntos
Endocardite Bacteriana/mortalidade , Peptídeo Natriurético Encefálico/sangue , Endocardite Bacteriana/sangue , Feminino , Mortalidade Hospitalar , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Curva ROC , Fatores de Risco
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA